YM 511: a non-steroidal aromatase inhibitor; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 177865 |
| CHEMBL ID | 108425 |
| SCHEMBL ID | 544997 |
| MeSH ID | M0253882 |
| Synonym |
|---|
| ym-511 |
| ym511 |
| bdbm10016 |
| 4-{[(4-bromophenyl)methyl](4h-1,2,4-triazol-4-yl)amino}benzonitrile |
| ym 511 |
| CHEMBL108425 |
| 4-[(4-bromophenyl)methyl-(1,2,4-triazol-4-yl)amino]benzonitrile |
| 148869-05-0 |
| benzonitrile, 4-(((4-bromophenyl)methyl)-4h-1,2,4-triazol-4-ylamino)- |
| ym511 (pharmaceutical) |
| benzonitrile,4-[[(4-bromophenyl)methyl]-4h-1,2,4-triazol-4-ylamino]- |
| SCHEMBL544997 |
| GGPPBTSXFROGAE-UHFFFAOYSA-N |
| 4-[n-(4-bromobenzyl)-n-(4-cyanophenyl)amino]-4h-1,2,4-triazole |
| AKOS024457519 |
| 4-[[(4-bromophenyl)methyl]-4h-1,2,4-triazol-4-ylamino]benzonitrile |
| DTXSID50164121 |
| 4-((4-bromobenzyl)(4h-1,2,4-triazol-4-yl)amino)benzonitrile |
| CS-0025228 |
| HY-105184 |
| TK6QEB6SVR |
| benzonitrile, 4-[[(4-bromophenyl)methyl]-4h-1,2,4-triazol-4-ylamino]- |
| ym 511 (pharmaceutical) |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 2 | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0002 | 1.1060 | 8.3000 | AID1796987 |
| Aromatase | Homo sapiens (human) | IC50 (µMol) | 0.0005 | 0.0000 | 1.2904 | 10.0000 | AID1796388; AID1798417; AID291837; AID53561; AID570240 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| arylesterase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| carbonate dehydratase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| protein binding | Carbonic anhydrase 2 | Homo sapiens (human) |
| zinc ion binding | Carbonic anhydrase 2 | Homo sapiens (human) |
| cyanamide hydratase activity | Carbonic anhydrase 2 | Homo sapiens (human) |
| iron ion binding | Aromatase | Homo sapiens (human) |
| steroid hydroxylase activity | Aromatase | Homo sapiens (human) |
| electron transfer activity | Aromatase | Homo sapiens (human) |
| oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen | Aromatase | Homo sapiens (human) |
| oxygen binding | Aromatase | Homo sapiens (human) |
| heme binding | Aromatase | Homo sapiens (human) |
| aromatase activity | Aromatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytoplasm | Carbonic anhydrase 2 | Homo sapiens (human) |
| cytosol | Carbonic anhydrase 2 | Homo sapiens (human) |
| plasma membrane | Carbonic anhydrase 2 | Homo sapiens (human) |
| myelin sheath | Carbonic anhydrase 2 | Homo sapiens (human) |
| apical part of cell | Carbonic anhydrase 2 | Homo sapiens (human) |
| extracellular exosome | Carbonic anhydrase 2 | Homo sapiens (human) |
| cytoplasm | Carbonic anhydrase 2 | Homo sapiens (human) |
| plasma membrane | Carbonic anhydrase 2 | Homo sapiens (human) |
| apical part of cell | Carbonic anhydrase 2 | Homo sapiens (human) |
| endoplasmic reticulum | Aromatase | Homo sapiens (human) |
| endoplasmic reticulum membrane | Aromatase | Homo sapiens (human) |
| membrane | Aromatase | Homo sapiens (human) |
| endoplasmic reticulum | Aromatase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID53561 | In vitro inhibition of [1-beta-3H]-androstenedione binding to Cytochrome P450 19A1 of JEG-3 human placental carcinoma cells | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | First dual aromatase-steroid sulfatase inhibitors. |
| AID570241 | Inhibition of steroid sulfatase in human JEG-3 cells using [6,7-3H]E1S after 1 hr by scintillation spectrometry | 2011 | ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3 | Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. |
| AID1599433 | Inhibition of human placental microsome aromatase using [1beta,2beta3H]androstenedione as substrate by liquid scintillation counting method | 2019 | European journal of medicinal chemistry, Sep-01, Volume: 177 | Estrogen signaling: An emanating therapeutic target for breast cancer treatment. |
| AID1249539 | Inhibition of aromatase in human placental microsome | 2015 | Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19 | Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. |
| AID291838 | Inhibition of steroid sulfatase in JEG3 cell membrane | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Dual aromatase-steroid sulfatase inhibitors. |
| AID1600043 | In vivo inhibition of aromatase in Wistar rat at 10 mg/kg, po relative to control | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179 | Sulfamates in drug design and discovery: Pre-clinical and clinical investigations. |
| AID1249542 | Invivo inhibition of steroid sulfatase in Wistar rat at 10 mg/kg, po administered as single dose measured after 3 hrs | 2015 | Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19 | Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. |
| AID205788 | In vitro inhibition of [6,7-3H]E1S binding to steroid sulfatase in JEG-3 human placental carcinoma cells; Not active | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | First dual aromatase-steroid sulfatase inhibitors. |
| AID291837 | Inhibition of aromatase in JEG3 cell membrane | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Dual aromatase-steroid sulfatase inhibitors. |
| AID570240 | Inhibition of aromatase in human JEG-3 cells using [1beta-3H]androstenedione after 1 hr by scintillation spectrometry | 2011 | ACS medicinal chemistry letters, Mar-10, Volume: 2, Issue:3 | Hybrid dual aromatase-steroid sulfatase inhibitors with exquisite picomolar inhibitory activity. |
| AID1249541 | Invivo inhibition of steroid sulfatase in Wistar rat liver at 10 mg/kg, po administered as single dose | 2015 | Journal of medicinal chemistry, Oct-08, Volume: 58, Issue:19 | Discovery and Development of the Aryl O-Sulfamate Pharmacophore for Oncology and Women's Health. |
| AID1798417 | Aromatase Inhibition Assay from Article 10.1021/jm061462b: \\Dual aromatase-steroid sulfatase inhibitors.\\ | 2007 | Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15 | Dual aromatase-steroid sulfatase inhibitors. |
| AID1796388 | Aromatase Assay from Article 10.1021/jm034033b: \\First dual aromatase-steroid sulfatase inhibitors.\\ | 2003 | Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15 | First dual aromatase-steroid sulfatase inhibitors. |
| AID1796987 | Carbonic Anhydrase Inhibition Assay from Article 10.1021/bi047692e: \\First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors.\\ | 2005 | Biochemistry, May-10, Volume: 44, Issue:18 | First crystal structures of human carbonic anhydrase II in complex with dual aromatase-steroid sulfatase inhibitors. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 5 (35.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (6.25%) | 5.53% |
| Reviews | 2 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 13 (81.25%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||